-22.6%
ADBE vs MRNA
+511.3%
-533.9%
-47.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -6.7% | -2.2% | -4.5% | -6.7% |
| 7D | -8.6% | +5.5% | -14.1% | -8.7% |
| 30D | +2.8% | +158.7% | -156.0% | -0.5% |
| 3M | +3.1% | +182.1% | -179.0% | -0.3% |
| 6M | -2.4% | +151.8% | -154.2% | -5.1% |
| YTD | -23.9% | +393.6% | -417.4% | -28.6% |
| 1Y | -22.6% | +499.5% | -522.1% | -29.0% |
| All | -22.6% | +511.3% | -533.9% | -29.0% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling